Anti-emetic therapy in cancer chemotherapy: Current status

Basic and Clinical Pharmacology and Toxicology

Volumn 101, Issue 3, 2007, Pages 143-150

  Herrstedt, Jørn ^a   Dombernowsky, Per ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450; CYTOTOXIN; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANISETRON; IDARUBICIN; IFOSFAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; OXALIPLATIN; PALONOSETRON; PROCARBAZINE; SEROTONIN 3 ANTAGONIST; STREPTOZOCIN; TROPISETRON; UNINDEXED DRUG;

ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONSTIPATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; EUPHORIA; EVIDENCE BASED PRACTICE; FLUSHING; HUMAN; INSOMNIA; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; SHORT SURVEY; SIDE EFFECT;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; NAUSEA; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, NEUROKININ-1; RECEPTORS, SEROTONIN, 5-HT3; VOMITING;

EID: 34547872714     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00122.x     Document Type: Short Survey

References (54)

1. 3 antagonists. Br J Cancer 1997 76 : 1055 61.
2. Thumas LJ. Über das Brechcentrum und über die Wirkung einiger pharmakologischer Mittel auf dasselbe [About the vomiting centre and about the effect of a pharmaceutical agent on the same]. Archieves für Patologische Anatomie 1891 123 : 44 69.
3. Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953 5 : 193 230.
4. 1-adrenergic receptors. Cancer Chemother Pharmacol 1993 33 : 53 6.
5. Hoyer D, Clarcke DE, Fozard JR et al. International Union of Pharmacology classification of receptors for 5-Hydroxytryptamine (serotonin). Pharmacol Rev 1994 46 : 157 203.
6. Herrstedt J, Aapro MS, Smyth JF, Del Favero A. Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 1998 6 : 204 14.
7. Morran C, Smith DC, Anderson DA, McArdle CS. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. Br Med J 1979 19 : 1323 4.
8. Moertel CG, Reitemeier RJ. Controlled studies of metopimazine for the treatment of nausea and vomiting. J Clin Pharmacol 1973 13 : 283 7.
9. Herrstedt J, Sigsgaard T, Handberg J et al. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during cisplatinum-based chemotherapy in patients with cancer. J Clin Oncol 1997 15 : 1690 6.
10. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P. Ondansetron plus metopimazine compared to ondansetron alone i patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993 328 : 1076 80.
11. Ioannidis PA, Hesketh PJ. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000 18 : 3409 22.
12. Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin acute emesis. J Clin Oncol 1998 16 : 2937 48.
13. Italian Group for Antiemetic Research. Randomized, double-blind, dose-finding study of dexamethasone in the prevention of acute emesis induced by anthracyclines, carboplatin and cyclophosphamide. J Clin Oncol 2004 22 : 725 9.
14. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 2007 18 : 233 40.
15. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003 11 : 137 43.
16. Gralla RJ, Itri L, Pisko S et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981 305 : 905 9.
17. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986 88 : 497 9.
18. Bonneterre J, Chevallier B, Metz R et al. A randomized, double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990 8 : 1063 9.
19. Kaasa S, Kvaloy S, Dicato MA et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 1990 26 : 311 4.
20. Marschner NW, Adler M, Nagel GA, Christmann D, Fennzl E, Upadhyaya B. Double-blind, randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 1991 27 : 1137 40.
21. Jones AL, Hill AS, Soukop M et al. Comparison of ondansetron and dexamethasone in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991 338 : 483 7.
22. De Mulder PHM, Seynaeve C, Vermorken JB et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990 113 : 834 40.
23. Marty M, Pouillart P, Scholl S et al. Comparison of the 5-hydroxytryptamine (serotonin), antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990 322 : 816 21.
24. Warr D, Willan A, Fine S et al. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 1991 83 : 1169 73.
25. Warr DG, Wilan A, Venner P et al. A randomized, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. Eur J Cancer 1993 29A : 33 6.
26. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone in the prevention of cisplatin-induced acute emesis. Ann Oncol 1995 6 : 805 10.
27. Gralla RJ, Navari RM, Hesketh PJ et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998 16 : 1568 73.
28. Perez EA, Hesketh PJ, Sandbach J et al. Comparison of single-dose, oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. A multicenter, double-blind, randomized parallel study. J Clin Oncol 1998 16 : 754 60.
29. 3 receptor antagonist. Cancer 2003 98 : 2473 82.
30. Gralla RJ, Lichinitser M, Van der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003 14 : 1570 7.
31. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006 17 : 1441 9.
32. von Euler VS, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol (Lond) 1931 72 : 577 83.
33. Chang M, Leeman SE. Isolation of sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J Biol Chem 1970 245 : 4784 90.
34. 1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 1987 89 : 817 18.
35. Cocquyt V, van Belle S, Reinhardt RR et al. Comparison of L-758298, a prodrug for the selective neurokinin-1 antagonist, L-754030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001 37 : 835 42.
36. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 1999 340 : 190 5.
37. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The aprepitant 052 study group. J Clin Oncol 2003 21 : 4112 9.
38. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003 97 : 3090 8.
39. Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006 17 : 4112 9.
40. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005 23 : 2822 30.
41. 1 antagonist aprepitant given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of 2 randomized, placebo-controlled phase III trials. Eur J Cancer 2004 40 : 403 10.
42. Herrstedt J, Muss HB, Warr DG et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005 104 : 1548 55.
43. Blower P, de Witt R, Goodin S, Aapro M. Drug-drug interactions in oncology: why are they important and can they be minimized? Clin Rev Oncol Hematol 2005 55 : 117 42.
44. Herrstedt J. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf 2004 3 : 231 48.
45. Nygren P, Hande K, Petty KJ et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005 55 : 609 16.
46. http://www.fda.gov. Merck background information package for the panel members of the advisory committee.
47. Blum RA, Majumdar A, McCrea J et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003 25 : 1407 19.
48. Antiemetic Subcommittee of MASCC. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006 17 : 20 8.
49. Kris MG, Hesketh PJ, Somerfield MR et al. ASCO guidelines for antiemetics in oncology: update 2006. J Clin Oncol 2006 24 : 2932 47.
50. Herrstedt J. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2007 18 : ii83 ii85.
51. Navari RM, Einhorn LH, Giovannini M et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group Study. Support Care Cancer 2005 13 : 529 34.
52. Rudd JA, Ngan MP, Wai MK et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 2006 392 : 79 83.
53. 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003 21 : 2147 55.
54. Grunberg SM, Osoba D, Hesketh PJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 2005 13 : 80 4.